Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017

Full Text:

Abstract

Aim. To assess the cost and importance of the vital and essential medicines for the treatment of 12 groups of internal diseases purchased in 2017 by the «key» medical organizations in the subjects of Russian Federation with the funding from the system of compulsory medical insurance.

Material and methods. We conducted the ABC and VEN analysis of the medications (according to the list of vital and essential medicines and clinical guidelines) treatment of 12 groups of internal diseases purchased in 2017 by the «key» medical organizations in the subjects of Russian Federation.

Results. The study revealed that medical organizations show insufficient level of registration (less than 10% of the key medical organizations) regarding the medicines prescribed in the groups of diseases according to ICD-10, which complicates conducting large-scale research aimed at assessing the clinical and economical relevance of the provided treatment. Despite the fact that during the process of purchasing by medical organizations they are guided by the list of vital and essential medicines, the percent of expenses for the medicines which are not in the list, is still very high (more than 20%). At the same time in most of the groups being assessed, in the most expensive group A (80% of expenses) there were the medications not included in the list of vital and essential medicines. 

Conclusion. Assessment of correspondence between the medicines purchased by the medical organizations and those recommended by the guidelines is complicated due to the absence of clinical guidelines for the wide range of internal diseases. According to the preliminary assessments, the wide range of medications mentioned in clinical guidelines compared to the list of vital and essential medicines significantly broaden the number of essential medicines from the point of VEN-analysis. 

About the Authors

O. M. Drapkina
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Professor, Corresponding Member of the Russian Academy of Sciences, Director,

Petroverigsky per. 10, Moscow, 101990 



A. V. Kontsevaya
National Medical Research Center for Preventive Medicine
Russian Federation

MD, PhD, Deputy Director for Science and Analytics,

Petroverigsky per. 10, Moscow, 101990 



M. V. Sura
Center for Healthcare Quality Assessment and Control
Russian Federation

MD, PhD, Head of Research Department, 

Khokhlovsky per. 10-5, Moscow, 109028 



R. N. Shepel
National Medical Research Center for Preventive Medicine
Russian Federation

MD, Head of Department of Management and Analysis of Medical Care; Researcher, Department of Fundamental and Applied Aspects of Obesity,

Petroverigsky per. 10, Moscow, 101990



L. M. Zhamalov
National Medical Research Center for Preventive Medicine
Russian Federation

MD, Head of Workgroup, Department of Management and Analysis of Medical Care,

Petroverigsky per. 10, Moscow, 101990 



References

1. Federal Law of 21.11.2011 N 323-FZ (as amended on 06.03.2019) “On the basis of the protection of public health in the Russian Federation” [cited by Sep 01, 2019]. Available from: http://www.consultant.ru/document/cons_doc_LAW_121895/. (In Russ.)

2. Sura M.V. Restrictive lists of drugs: regulations, functions, sources of finance, and guidelines for creation. Farmakoekonomika. Modern Pharmacoeconomic and Pharmacoepidemiology. 2017;10(1):46- 56 (In Russ.)

3. The Order of the MHIF of 01.12.2010 N 230 (ed. Dated February 22, 2017) “On approval of the procedure for organizing and conducting the monitoring of volumes, terms, quality and conditions of providing medical care for compulsory health insurance” (Registered in the Ministry of Justice of Russia on January 28, 2011 N 19614). [cited by Sep 01, 2019]. Available from: http://www.consultant.ru/document/cons_doc_LAW_110198/]. (In Russ.)

4. Letter of the Ministry of Health of Russia N 11-7 / 10 / 2-7543, FFOMS N 14525 / 26-1 / dated 11/21/2018 “On the methodological recommendations on how to pay for medical care at the expense of compulsory health insurance” [cited by Sep 01, 2019]. Available from: http://www.ffoms.ru/news/ffoms/ministerstvom-zdravookhraneniya-rf-i-foms-utverzhdenymetodicheskie-rekomendatsii-po-sposobam-oplaty/. (In Russ.).

5. Instructions on grouping cases, including the rules for taking into account classification criteria, and approaches to paying for medical care on an outpatient basis under the per capita financing standard, were sent to the constituent entities of the Russian Federation by letter of the Federal Mandatory Medical Insurance Fund (dated 03.12.2018 No. 15031/26 1 / i) [cited by Sep 01, 2019]. Available from: http://www.ffoms.ru/news/ffoms/pismo-federalnogo-fonda-obyazatelnogo-meditsinskogostrakhovaniya-ot-03-12-2018-15031-26-1-i/. (In Russ.).

6. Resolution of the Government of the Russian Federation of 29.10.2010 N 865 (ed. 08.10.2018) “On state regulation of prices for medicines included in the list of vital and essential medicines” [cited by Sep 01, 2019]. Available from: http://www.consultant.ru/document/cons_doc_LAW_106310/. (In Russ.).

7. Decree of the Government of the Russian Federation of 08.08.2009 N 654 (ed. 03.02.2016) “On the improvement of state regulation of prices for medicines included in the list of essential and essential medicines” [cited by Sep 01, 2019]. Available from: http://www.consultant.ru/document/cons_doc_LAW_90501/. (In Russ.).

8. Order of the Government of the Russian Federation of 28.12.16, No. 2885-p “List of vital and essential drugs for medical use in 2017” [cited by Sep 01, 2019]. Available from: http://www.consultant.ru/document/cons_doc_LAW_210292/. (In Russ.)

9. Imaeva A.E., Balanova Y.A., Kontsevaya A.V., et al. Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation. Rational Pharmacotherapy in Cardiology. 2018;14(6):804-15 (In Russ.)

10. Khayatov A.R., Egorova S.N., Garifullina G.K., et al. Pharmacological support of children's multi-specialty in-patient hospitals: compliance of purchased drugs with the list of vital and most important drugs. Medical Almanac. 2018;(6):162-5 (In Russ.) DOI:10.21145/2499-9954-2018-6-162-165.


For citation:


Drapkina O.M., Kontsevaya A.V., Sura M.V., Shepel R.N., Zhamalov L.M. Costs and Evaluation of Vital and Essential Medicines for Internal Diseases Treatment, Purchased by Medical Organizations with the Funding from the System of Obligatory Medical Insurance in 2017. Rational Pharmacotherapy in Cardiology. 2019;15(5):681-689. (In Russ.)

Views: 16


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)